Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EVX-01 · 1 trial · 2 indications
Composite of a BOR of complete response (CR) or PR for patients with SD at the time of first EVX-01 administration and a BOR of CR for patients with PR at the time of first EVX-01 administration, within 2 years of treatment with pembrolizumab, as per RECIST 1.1 criteria
| Arm | Type | Description |
|---|---|---|
| EVX-01 in combination with pembrolizumab | EXPERIMENTAL | EVX-01 is administered im. Pembrolizumab is administered according to label |
| Name | Type | Description |
|---|---|---|
| EVX-01 | DRUG | Investigational drug given in combination with standard of care |
| Pembrolizumab 25 MG/ML | DRUG | Standard of care |
Inclusion Criteria: * Be at least 18 years of age on day of signing informed consent. * Histologically confirmed, and not amenable to local therapy, metastatic or unresectable melanoma Stage III or Stage IV, as per AJCC 8th ed. staging system. 1. Patient may not have a diagnosis of uveal or ocul...
EVX-01 is an investigational small molecule being studied for the treatment of Stage IV melanoma, specifically in adults with unresectable or metastatic melanoma. It is currently in Phase 2 clinical development and is being evaluated in combination with pembrolizumab.
EVX-01 is being developed by Evaxion A/S, a biotech company listed on the stock exchange under the ticker EVAX. The company is conducting a Phase 2 clinical trial to evaluate the safety and efficacy of EVX-01 in combination with pembrolizumab in patients with advanced melanoma.
EVX-01 is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to assess its safety and efficacy for treating Stage IV melanoma.
EVX-01 is being studied in a single Phase 2 clinical trial with the identifier NCT05309421. This trial is evaluating the efficacy and safety of EVX-01 in combination with pembrolizumab in adults with unresectable or metastatic melanoma. The trial is active but not recruiting participants.
EVX-01 is a small molecule therapeutic. The specific molecular target or mechanism of action has not been disclosed in available information, so its precise mode of action in treating melanoma is not publicly detailed.